• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Arylacetamide deacetylase (AADAC), Truncated

E.coli expressed Recombinant Human Arylacetamide deacetylase(AADAC) is a partial-length protein containing 376 amino acids. It carries a 10xHis-SUMO-tag at the N-terminus and a Myc-tag at the C-terminus. Its expression region is the 24-399aa of the human AADAC protein. The LC-MS/MS Analysis validated its identity and SDS-PAGE determined its purity. Its purity is greater than 90%. This protein is in-stock so that it will reach your lab bench faster. In addition to serving as an immunogen for antibody synthesis, the recombinant AADAC protein may also be used to investigate whether it is involved in the breakdown of certain drugs. AADAC is a serine hydrolase that widely catalyzes the hydrolysis of some clinically used drugs. AADAC is primarily expressed in the human intestine and liver and is responsible for the hydrolysis of flutamide, phenacetin, and rifampicin. It is closely related to kidney failure and hepatotoxicity in some patients after taking flutamide or phenacetin.

ACP02329

E.coli expressed Recombinant Human Arylacetamide deacetylase(AADAC) is a partial-length protein containing 376 amino acids. It carries a 10xHis-SUMO-tag at the N-terminus and a Myc-tag at the C-terminus. Its expression region is the 24-399aa of the human AADAC protein. The LC-MS/MS Analysis validated its identity and SDS-PAGE determined its purity. Its purity is greater than 90%. This protein is in-stock so that it will reach your lab bench faster. In addition to serving as an immunogen for antibody synthesis, the recombinant AADAC protein may also be used to investigate whether it is involved in the breakdown of certain drugs.
AADAC is a serine hydrolase that widely catalyzes the hydrolysis of some clinically used drugs. AADAC is primarily expressed in the human intestine and liver and is responsible for the hydrolysis of flutamide, phenacetin, and rifampicin. It is closely related to kidney failure and hepatotoxicity in some patients after taking flutamide or phenacetin.

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP02329 Target NameAADAC
Target SynonymsAAAD_HUMAN; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DACFormLiquid or Lyophilized powder
Expression SystemE.coliExpression Range24-399aa
Mol Weight63.1kDaProtein LengthPartial
PurityGreater than 90% as determined by SDS-PAGE.Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP22760
Background Information
  • Uniprot Id

    P22760

  • Target Species

    Human

  • Target Name

    AADAC

  • Target Full Name

    Arylacetamide deacetylase

  • Target Function

    Displays cellular triglyceride lipase activity in liver, increases the levels of intracellular fatty acids derived from the hydrolysis of newly formed triglyceride stores and plays a role in very low-density lipoprotein assembly. Displays serine esterase activity in liver. Deacetylates a variety of arylacetamide substrates, including xenobiotic compounds and procarcinogens, converting them to the primary arylamide compounds and increasing their toxicity.

  • Target Subcellular Location

    Endoplasmic reticulum membrane; Single-pass type II membrane protein. Microsome membrane; Single-pass type II membrane protein.

  • Target Protein Families

    'GDXG' lipolytic enzyme family

  • Target Tissue Specificity

    Detected in liver (at protein level). Mainly expressed in liver, small intestine, colon, adrenal gland and bladder.

  • Target Research Area

    Signal Transduction

  • Target Synonyms

    AAAD_HUMAN; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC

  • Target Background

    Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens

Inquire Recombinant Human Arylacetamide deacetylase (AADAC), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification